Workflow
医药板块投资
icon
Search documents
四环医药投资入股瑞士水光针公司,恒生医疗ETF(513060)近15日“吸金”合计1.77亿元
Sou Hu Cai Jing· 2025-10-14 05:50
截至2025年10月14日 13:23,恒生医疗保健指数下跌2.74%。成分股方面涨跌互现,上美股份领涨2.08%,京东健康上涨1.46%,讯飞医疗科技上涨1.23%;微 创机器人-B领跌7.19%,石药集团下跌5.71%,医脉通下跌5.26%。恒生医疗ETF(513060)下跌1.74%,最新报价0.68元。拉长时间看,截至2025年10月13日, 恒生医疗ETF近3月累计上涨18.15%,涨幅排名可比基金1/3。 流动性方面,恒生医疗ETF盘中换手12.72%,成交8.84亿元,市场交投活跃。拉长时间看,截至10月13日,恒生医疗ETF近1年日均成交17.46亿元,排名可 比基金第一。 截至2025年10月14日 13:23,恒生港股通创新药精选指数下跌3.58%。成分股方面涨跌互现,山东新华制药股份领涨1.12%,映恩生物-B上涨0.51%,同源康 医药-B上涨0.46%;科伦博泰生物-B领跌8.29%,石药集团下跌5.71%,丽珠医药下跌4.69%。港股创新药精选ETF(520690)下跌2.28%,最新报价0.94元。 流动性方面,港股创新药精选ETF盘中换手21.74%,成交9047.25万元,市 ...
医药板块延续涨势,恒生创新药ETF(159316)、医药ETF(512010)等产品助力布局板块龙头
Sou Hu Cai Jing· 2025-07-30 05:16
Group 1 - The core viewpoint of the news highlights the performance of various healthcare indices, with the CSI Hong Kong Stock Connect Healthcare Index rising by 2%, the CSI 300 Healthcare Index increasing by 1.7%, and the Hang Seng Hong Kong Stock Connect Innovative Drug Index up by 1.5% [1][4][11] - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading companies in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related industries [3] - The CSI Innovative Drug Industry Index targets leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [6] - The CSI Biotechnology Theme Index centers on leading A-share biotechnology companies, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [8] - The CSI 300 Healthcare Index encompasses leading A-share healthcare companies, covering segments such as chemical pharmaceuticals, medical services, and medical devices [10]
港股医药ETF(159718)近2周新增规模居同类第一,医疗创新ETF(516820)最新单日净流入超1300万元,机构:医药板块仍是值得重点配置方向
Sou Hu Cai Jing· 2025-04-28 03:31
Core Insights - The healthcare sector in Hong Kong is experiencing mixed performance, with the 中证港股通医药卫生综合指数 down by 2.09% as of April 28, 2025, while the 港股医药ETF has shown a weekly increase of 6.99% as of April 25, 2025 [1][4][7] Group 1: Market Performance - The 中证港股通医药卫生综合指数 has decreased by 2.09% as of April 28, 2025, with notable gainers including 心泰医疗 up 6.75% and 国药控股 up 3.79% [1] - The 港股医药ETF has a latest price of 0.7 yuan, reflecting a 2.09% decline, but has seen a 6.99% increase over the past week [1] - The 中证医药及医疗器械创新指数 has decreased by 0.52% as of April 28, 2025, with 百利天恒 leading gains at 4.77% [4] Group 2: Liquidity and Trading Activity - The 港股医药ETF had a turnover rate of 16.09% with a trading volume of 42.87 million yuan, indicating active market participation [1] - The 医疗创新ETF had a turnover rate of 1.2% and a trading volume of 19.80 million yuan [4] - The 港股医药ETF has seen a significant increase in scale, growing by 52.31 million yuan over the past two weeks [1] Group 3: Fund Flows and Investment Trends - The 港股医药ETF has attracted a total of 37.93 million yuan in net inflows over the last five trading days [1] - The 医疗创新ETF has recorded a net inflow of 13.66 million yuan, with a total of 14.22 million yuan over the last ten trading days [4] - Leverage funds are increasingly being utilized, with the 医疗创新ETF showing a financing buy amount of 4.79 million yuan [4] Group 4: Company Developments - Several innovative pharmaceutical companies in Shanghai have reported profitability driven by sales of innovative products, highlighting their full-chain innovation capabilities [7] - The trend of going global is common among these innovative drug companies, with products like 呋喹替尼 receiving approval in the U.S. market [7] - The integration of "R&D-production-sales" is accelerating, with leading pharmaceutical companies transitioning from biotech to biopharmaceutical firms [8]